PDCD1 and melanoma: Besides, patients with advanced melanoma (stage III or IV) could experience long-term toxicities after termination of anti-PD-1, and up to 43.2% of patients developed chronic irAEs (defined as irAEs persisting for at least 12 weeks after anti–PD-1 therapy cessation) (Patrinely et al., 2021).